Reported about 1 year ago
Shares of GSK are decreasing after the CDC adjusted its guidance on RSV vaccine dosages for older individuals. This change in recommendation could impact GSK's future. The CDC now suggests older seniors from 65 to 70 consider the vaccine only for severe conditions, reducing the market size for companies like GSK, Pfizer, and Moderna. Moderna also faced setbacks with lower efficacy results, affecting the anticipated market opportunities for these companies.
Source: YAHOO